ReviewCurrent medicinal chemistry2016
Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.
Review in Current medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed.
- Trial
- A cholecystokinin B receptor antagonist and cocaine interaction, phase I study.CNS neuroscience & therapeutics · 2019Trial
- Triarylselenonium triflates provide efficient access to no-carrier-addedChemical science · 2026Article
- Carbon-11 Production: Communication, Operations, Maintenance, Troubleshooting, and Analysis for Maintaining High-Grade Bombardment and Provisions of [Molecules (Basel, Switzerland) · 2026Article
- Illuminating proinflammatory myeloid cells with PET tracers targeting GPR84.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Synthesis and Preclinical Evaluation of [ACS omega · 2026Article
- A Study of 3-Substituted 7-Methoxy-2,3,4,5-tetrahydro-1Molecules (Basel, Switzerland) · 2026Article
- Discovery and in vivo evaluation of a fluorine-18 pro-drug tracer for imaging sphingosine-1-phosphate receptor 2 in the brain.Bioorganic & medicinal chemistry · 2026Article
- Development of a novelActa pharmaceutica Sinica. B · 2025Article
- Toward Brain NaPharmaceuticals (Basel, Switzerland) · 2025Article
- Imaging poly(ADP-ribose) polymerase-1 (PARP1)Acta pharmaceutica Sinica. B · 2025Article
- Refining seizure foci localization: the potential of TSPO-PET.Acta epileptologica · 2025Review
- Development and Preclinical Characterization of [Journal of medicinal chemistry · 2025Article
- Multifactorial analysis of radiochemical purity in high-activityEJNMMI radiopharmacy and chemistry · 2025Article
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates.Cells · 2025Review
- Structure-Activity Relationships and Evaluation of 2-(Heteroaryl-cycloalkyl)-1Journal of medicinal chemistry · 2025Article
- Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders.RSC medicinal chemistry · 2025Review
- Expanding tracer space for positron emission tomography with high molar activityNature communications · 2025Article
- RadiolabeledFrontiers in nuclear medicine · 2025Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The development of reversibly binding radioligands for imaging brain proteins in vivo, such as enzymes, neurotransmitter transporters, receptors and ion channels, with positron emission tomography (PET) is keenly sought for biomedical studies of neuropsychiatric disorders and for drug discovery and development, but is recognized as being highly challenging at the medicinal chemistry level. This article aims to compile and discuss the main considerations to be taken into account by chemists embarking on programs of radioligand development for PET imaging of brain protein targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.